The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Malignancies|Stomach Cancer|Non-small Cell Lung Cancer|Esophageal Cancer|Breast Cancer|Ovary Cancer|Cervical Cancer
Interventions: DRUG: Apatinib
Sponsor: Shandong Cancer Hospital and Institute